Sprout Pharmaceuticals CEO Cindy Whitehead, the woman behind the approval of "female Viagra" in August, is leaving the company four months after it was acquired by Valeant Pharmaceuticals.
Whitehead saw Addyi (flibanserin) through its FDA approval in August. Sprout was acquired by Valeant for $1 billion was announced the same week.
"It became clear for us I think very quickly that Valeant was the right partner because our entire team stays, and we will run this, and we will continue to do this in a way that we see is right for women," she said.
That tune has changed quickly.
“I feel like I’ve seen it through to what I wanted to accomplish,” Whitehead told Bizwomen.com. “It really was to prove the science, get the approval so that women could have this choice for themselves and then really to build the team to have it really come to the realization of the bigger mission, which is the opportunity for this to go global and to be made widely available to women in an affordable way.”
Addyi officially went on market in October, and in its first month only saw 227 prescriptions get filled for its drug, which is designed to spark sexual desire in women suffering from hypoactive sexual desire disorder (HSDD), where they have a chronically low desire to have sex.
“Thanks to the efforts of Cindy and her team, Valeant has the opportunity to make Addyi broadly available to patients in need of this important medical treatment," Valeant spokeswoman Laurie Little said in an emailed statement. "Having built a team to take Addyi to market, we mutually agreed that it was the right time to transition to new leadership for the next phase of global commercialization."
Little added that Whitehead will stay on as a consultant to Sprout.
Выглядим стильно и модно при помощи этих ярких образов
Россиян предпочли туркам: в Турции, в отеле забитом российскими туристами, сломались кондиционеры и отдыхающие начали со скандалом перетаскивать кровати в ресторан
Буравят кожу. Профессор рассказала, как не подцепить паразитов при купании
Дата запуска новой системы въезда / выезда из ЕС перенесена: российским туристам теперь надо в ней зарегистрироваться
D&D's new 2024 Player's Handbook will have 10 species to choose from including goliaths, and drow will be closer to their Baldur's Gate 3 version
Интервью AppTime с компанией Innova: релиз Gran Saga в России, внутриигровая оплата и «Масленица» в корейской MMO
Двадцать пять человек за одним столом под звуки караоке – это было шедеврально!
According to BioWare, Dragon Age: The Veilguard is the first entry in the series where "the combat's actually fun" and where characters are "intentionally" the focus of the storytelling, which seems pretty unfair on the first three games
Brad Barket/Getty